Anti-venom-induced myelopathy in a semipoisonous snakebite

Area of Science:

• Neurology
• Immunology
• Toxicology

Background:

• Snakebite envenomation necessitates prompt administration of antivenom to neutralize venom toxins.
• Polyvalent antivenom, derived from equine sources, is a critical therapeutic agent for diverse snake species.
• The use of antivenom in cases of suspected envenomation, even with potentially less potent venomous snakes, remains a subject of clinical consideration.

Observation:

• A 40-year-old female patient developed myelopathy with Brown Sequard syndrome following administration of polyvalent equine antivenom.
• Diagnostic imaging ruled out hematomyelia, suggesting an alternative etiology for the neurological deficit.
• The patient's symptoms were attributed to an immunological inflammatory response of the spinal cord.

Findings:

• Antivenom administration, while life-saving, can precipitate rare immunological complications.
• Myelopathy presenting as Brown Sequard syndrome is a potential, albeit uncommon, adverse reaction to equine-derived antivenom.
• The case underscores the complex interplay between venom toxins, the immune system, and therapeutic interventions.

Implications:

• Further investigation into the immunological mechanisms underlying antivenom-induced myelopathy is warranted.
• Clinical guidelines may need to consider the risk-benefit ratio of antivenom in specific snakebite scenarios.
• Enhanced monitoring for neurological adverse events post-antivenom administration is crucial for patient safety.